LRRK2 inhibitors (Origenis)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLRRK2 inhibitors (Origenis)
Drug Alias NameLRRK2 inhibitors (Origenis)leucine-rich repeat kinase 2 inhibitors (Origenis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOrigenis GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOrigenis GmbH
Active IndicationsN/A
Inactive IndicationsCentral Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A